By: Sruthy Iype  Sep. 11, 2020

Dexur’s analysis of Medicare claims data showed that Darzalex is used in six times as many multiple myeloma patients compared to Empliciti. The analysis looked at the J code usage of the drugs (J9145/J9176) among Medicare patients who received treatment in hospital outpatient settings between Jan 2017 and Dec 2019. The analysis also looks at the average claims per patient data, which is a proxy for the number of injections / IV infusions / doses administered to a patient.

By: Parvathy Rajagopal  Sep. 11, 2020

Dexur’s analysis of Medicare Claims data showed an In-hospital Mortality Rate of 37% among Covid hospitalized patients during March 2020 for New York State. Medicare Insurance is provided to people in the US generally over the age of 65 so the data outcomes is of an older population which could explain the much higher in hospital mortality rates for this cohort compared to the general population. Among the top 20 hospitals with the highest Covid Hospitalizations, the data revealed that NewYork Presbyterian - Weill Cornell Medical Center had the lowest mortality rate of <18% while Jamaica Hospital Medical Center had the highest in hospital mortality rate of 59.4%. The lowest in hospital mortality rates were in Manhattan Hospitals at 18-27% and the highest were in the Queens & Brooklyn area with more than 50%.

By: Sruthy Iype  Sep. 10, 2020

Dexur’s analysis of Medicare claims data showed that Ocrevus is used in twice as many multiple sclerosis patients as compared to Tysabri. The analysis looked at the J code usage of the drugs (J2350/J2323) among Medicare patients who received treatment in hospital outpatient settings between Jan 2018 and Dec 2019. The analysis also looks at the average claims per patient data, which is a proxy for the number of injections / IV infusions / doses administered to a patient.

By: Sruthy Iype  Sep. 10, 2020

Dexur’s analysis of Medicare claims data showed that Keytruda has three times the market share as Opdivo in lung cancer, whereas Opdivo has twice the market share as Keytruda in Melanoma. The analysis looked at the J code usage of the drugs (J9271/J9299) among Medicare patients who received treatments in hospital outpatient settings between Jan and Dec 2019. The analysis also looks at the average claims per patient data, which is a proxy for the number of injections / IV infusions / doses administered to a patient.

By: Parvathy Rajagopal  Sep. 09, 2020

Dexur’s analysis of Medicare claims of hospitals within a 10-mile radius of Alexandria, Louisiana, showed that CHRISTUS St. Frances Cabrini Hospital and Rapides Regional Medical Center had the best value outcomes over a 90-day episode for Sepsis. Dexur’s value analysis tracks a patient’s episode of care from the date of admission for 90 days, including the index hospitalizations, rehospitalization, home health, nursing home, and ED costs. The total cost of care data helps patients make appropriate choices and helps local ACOs make appropriate referrals choices. The analysis was risk-adjusted, for alive and non-hospice patients and was done at the DRG level, specifically DRG 871: Septicemia or Severe Sepsis without MV >96 Hours with Major Complication or Comorbidity, to adjust for complications and comorbidities.

By: Parvathy Rajagopal  Sep. 09, 2020

Dexur’s analysis of medicare claims of hospitals within a 10-mile radius of Billings, Montana, showed that St. Vincent Healthcare and Billings Clinic Hospital had the best value outcomes over a 90 day episode for Hip & Knee replacement. Dexur’s value analysis tracks a patient’s episode of care from the date of admission for 90 days and includes the index hospitalizations, rehospitalization, home health, nursing home, and ED costs. Total cost of care data helps patients make appropriate choices and helps local ACOs like Billings Clinic and Rocky Mountain Accountable Health Network, Inc., make appropriate referral choices. The analysis was risk-adjusted, for alive and non-hospice patients and was done at the DRG level, specifically DRG 470: Major Joint Replacement or Reattachment of Lower Extremity without Major Complication or Comorbidity (MCC), to adjust for complications and comorbidities.

By: Sruthy Iype  Sep. 08, 2020

Dexur’s analysis of Medicare claims data showed a 10 percent increase in Stelara’s use (ustekinumab) among patients of Crohn’s disease in 2019, as compared to 2018. The study looks at the J code (J3357) usage of Stelara among Medicare patients diagnosed with plaque psoriasis, Crohn’s disease, and psoriatic arthritis who received outpatient services at hospitals between Jan 2017 and Dec 2019.

By: Neha Thomas  Sep. 08, 2020

Dexur’s analysis of medicare claims of hospitals within a 10-mile radius of Jefferson City, Missouri, showed that SSM Health St. Mary's Hospital - Jefferson City and Capital Region Medical Center had the best value outcomes over a 90 day episode for Sepsis. Dexur’s value analysis tracks a patient’s episode of care from the date of admission for 90 days and includes the index hospitalizations, rehospitalization, home health, nursing home, and ED costs. Total cost of care data helps patients make appropriate choices and helps local ACOs make appropriate referral choices. The analysis was risk-adjusted, for alive and non-hospice patients and was done at the DRG level, specifically DRG 871: Septicemia or Severe Sepsis without MV >96 Hours with Major Complication or Comorbidity, to adjust for complications and comorbidities.

By: Sruthy Iype  Sep. 07, 2020

Dexur’s analysis of Medicare claims data showed that more than 50 percent of Tecentirq’s use is associated with the treatment of lung cancer patients, followed by patients of bladder cancer and breast cancer. The analysis looked at the J code (J9022) usage of the drug among Medicare patients who received outpatient care between Jan 2018 and Dec 2019. The analysis also looks at the average claims per patient data, which is a proxy for the number of injections / IV infusions / doses administered to a patient.

By: Sruthy Iype  Sep. 04, 2020

Dexur’s analysis of Medicare claims data showed that head and neck cancer accounts for nearly 50 percent of the total patients who were administered Erbitux, followed by colorectal cancer and squamous cell carcinoma of the skin. The analysis was based on the J code (J9055) usage of the drug among Medicare patients who received outpatient care between Jan 2017 and Dec 2019.

Erbitux (cetuximab) is a monoclonal antibody that belongs to the drug class called epidermal growth factor receptor (EGFR) inhibitors. The binding of epidermal growth factor to EGFR, a transmembrane protein found on the surface of cells, sets off a series of events that result in cell growth and differentiation. In certain types of cancer, the overexpression of EGFR was found to be responsible for unregulated cell proliferation and tumor growth. By targeting the receptor and blocking the events mediated by it, Erbitux helps in slowing down the progression and spread of the disease. It is approved as a targeted therapy, monotherapy or in combination with other drugs, in the treatment of certain types of colorectal, and head and neck cancer.